Harbour Star Capital Inc. “TSXV:HSC.P” (to become “EAST”) (“Harbour Star” or the “Company”) and 1011705 B.C. Ltd. doing business as EastWest Science (“Eastwest”) are pleased to announce that they have closed the previously announced Qualifying Transaction.
EastWest’s shareholders approved the amalgamation of EastWest with 1129971 B.C. Ltd., a wholly owned subsidiary of Harbour Star, at the annual and special meeting of EastWest shareholders on June 29, 2018. The amalgamation was completed on July 16, 2018 (the “Closing”), and as a result, EastWest became a wholly owned subsidiary of the Company and the Company will carry on the business under the name the “EastWest Bioscience Group” until such time as the name change can be approved by the shareholders of Harbour Star.
The following individuals comprise the directors and officers of the Compnay: Rodney Gelineau (President, Chief Executive Officer and a Director); Richard Shatto (Vice President, Marketing and Administration), Geoffrey Balderson (Chief Financial Officer), Scott Reeves (Chairman and a Director), Mohammad Fazil (Director), John MacPhail (Director), and Douglas Horne (Director). Detailed profiles of the individuals that have been appointed officers and directors of the Company are included in the Filing Statement of the Company which has been filed on SEDAR under the Company’s profile at www.sedar.com. In addition, the profile of Scott Reeves is provided here: Scott Reeves (LL.B (Hons.’95), B.Comm (Hons. ’91)) is a partner at TingleMerrett LLP, a Calgary-based corporate and securities boutique focused on securities, corporate finance and commercial transactions for emerging and growth companies, joint ventures and partnerships. He has advised numerous private and public corporations (including registered dealers) in a wide range of business matters including access to capital markets, corporate governance and operational issues both nationally and internationally. He acts for a large number of TSX, TSX Venture Exchange and CSE-listed companies in a wide range of industries, including cannabis, oil and gas, mining, technology, biotechnology and industrial issuers. He has extensive experience in financing options, private equity and public offerings, public listings and exchange matters, corporate acquisitions, share and asset acquisitions and dispositions, restructurings, securities regulatory requirements for issuers and dealers and other related business transactions. He also acts a director and/or corporate secretary for many public and private companies, providing detailed corporate governance and continuous disclosure advice to his clients. He is a member of the advisory boards of both the TSX Venture Exchange and CSE, has acted as a lead instructor for the Masters degree program in eBusiness from Osgoode Hall Law School and has taught advanced corporate finance and corporations law at the University of Alberta’s Faculty of Law.
The TSX Venture Exchange (the “Exchange”) has previously granted conditional acceptance in respect of the listing of the common shares of the Company resulting from the Qualifying Transaction (the “Common Shares”), subject to receipt of final submission documents, which have now been delivered to the Exchange. Pending satisfactory review of such final materials by the Exchange, it is expected that the Company will be listed on the Exchange as a Tier 2 issuer and that trading of the Common Shares under the new symbol, “EAST” will commence at the opening of markets on or about Wednesday, July 25, 2018.
In connection with the Closing, Harbour Star issued an aggregate of 67,470,707 Common Shares to former holders of common shares of EastWest and an aggregate of 2,375,000 options to the current directors, officers and employees of the Company to acquire Common Shares at a price of $0.15 per share for a period of 5 years. Compensation warrants that were previously issued by EastWest to eligible parties in connection with private placements conducted by EastWest, have been exchanged for an equivalent right to purchase an aggregate of 327,850 shares of Harbour Star at a price of either $0.10 or $0.15 per share for a period of 12 months from the original date of issue. In addition, the founding group of shareholders of Harbour Star as a CPC sold an aggregate of 1,200,000 Common Shares to Rodney Gelineau and John MacPhail (as to 600,000 each) at a price of Cdn$0.075 per share. All of such shares will be transferred within escrow and are subject to the Company’s CPC Escrow Agreement.
As a result of the foregoing, the outstanding capital of the Company upon completion of the Qualifying Transaction consists of 75,118,207 Common Shares; options to acquire 2,375,000 Common Shares (comprised of the newly granted options noted above and the existing options granted by the Company as a CPC), and compensation warrants to purchase 1,134,417 Common Shares.
An aggregate of 19,840,000 Common Shares will be subject to 36-month escrow restrictions, with five percent (5%) being releasable upon receipt of final Exchange approval; a further five percent (5%) releasable in six (6) months; a further ten percent (10%) releasable on each of twelve (12) and eighteen (18) months; a further fifteen percent (15%) releasable on each of twenty-four (24) and thirty (30) months and the final forty percent (40%) releasable on thirty-six (36) months. An aggregate of 10,330,000 Common Shares (including the original 2,080,000 Common Shares under the CPC Escrow Agreement) will be subject to 36-month escrow restrictions, with ten percent (10%) of such escrowed shares being releasable upon receipt of final Exchange approval and a further fifteen percent (15%) being releasable on each of the six-month, twelve-month, eighteen-month, twenty-four month, thirty month and thirty-six month anniversaries of such approval.
For further details regarding the Qualifying Transaction are contained in Filing Statement of the Company that was filed on July 4, 2018 and is available under the Company’s profile at www.sedar.com. Readers are encouraged to make reference to the Filing Statement of the Company.
EastWest is a health and consumer products group of companies that is strategically positioned to enter mainstream consumer markets with holistic natural products. To date, EastWest has developed distribution channels into mainstream stores and markets in Canada. EastWest is also interested in markets in the USA and strategic international markets in Asia and Europe. The Company’s long term strategy is to complete a vertical integration, seed-to-sale strategy forming a strategic alliance with an open-field hemp growing and hemp seed processing company to facilitate the provision of Health Canada-approved hemp products for use in Health Canada-approved health and consumer products. EastWest’s current product are divided into four brands: (1) “Natural Advancement” – a line of Health Canada-approved natural health products; (2) “Earth’s Menu” – a line of foods; (3) “Natural Pet Science” – a line of pet food and pet supplement products; and (4) “ChanvreHemp” – a line of natural cosmetics and skin care products.
For further information, please contact:
Director of Harbour Star Capital Inc.
Telephone: (403) 613-7310
For further information about EastWest, please contact:
Telephone: (800) 409-1930, Ext 200
Early Warning Reports
In connection with the completion of the Qualifying Transaction, Rodney Gelineau (President, Chief Executive Officer and a Director of the Company) acquired ownership of 14,600,000 Common Shares and options to acquire 250,000 Common Shares, representing approximately 19.4% of the issued and outstanding Common Shares (undiluted) (19.6% including exercise of the options). The Common Shares acquired by Mr. Gelineau were acquired for investment purposes. In the future, Mr. Gelineau may acquire additional securities of the Company, subject to escrow provisions, dispose of some or all of the securities he now holds, or may continue to hold his current position. Mr. Gelineau entered into a Surplus Security Escrow Agreement dated July 16, 2018 (in respect of 14,000,000 Common Shares) and agreed to be bound by a previously existing CPC Escrow Agreement (in respect of 600,000 Common Shares). Each of the foregoing agreements imposes 36-month escrow restrictions on the Common Shares held by Mr. Gelineau, with different release terms. The CPC Escrow Agreement provides for ten percent (10%) of such escrowed shares being releasable upon receipt of final Exchange approval and a further fifteen percent (15%) being releasable on each of the six-month, twelve-month, eighteen-month, twenty-four month, thirty month and thirty-six month anniversaries of such approval. The Surplus Escrow provides for five percent (5%) being releasable upon receipt of final Exchange approval; a further five percent (5%) releasable in six (6) months; a further ten percent (10%) releasable on each of twelve (12) and eighteen (18) months; a further fifteen percent (15%) releasable on each of twenty-four (24) and thirty (30) months and the final forty percent (40%) releasable on thirty-six (36) months. An early warning report will be filed by Mr. Gelineau in accordance with applicable securities laws. To obtain a copy of the early warning report, please refer to the Company’s SEDAR profile at www.sedar.com.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of the release.
Except for statements of historical fact relating to the Company, the information contained herein constitutes forward-looking statements. Forward-looking statements are based on the opinions and estimates of management at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. Except as required by applicable securities requirements, the Company undertakes no obligation to update forward-looking statements if circumstances or management’s estimates or opinions should change. The reader is cautioned not to place undue reliance on forward-looking statements.
Ayurcann Holdings Corp. (CSE: AYUR) (the “Company” or “Ayurcann”) an integrated Canadian extraction company specializing in the processing of cannabis and hemp for the production of oils and various derivative products, announces the granting of stock options and restricted share units.
The Company has announced that it has granted incentive stock options to directors, officers, employees and consultants of the Company to purchase an aggregate of 1,000,100 common shares under the Company’s Stock Option Plan. Each option is exercisable at a price of $0.16 per common share, expires three years from the date of grant and vest six months from the date of the grant.
The Company has also granted restricted share unit grants, pursuant to the Company’s Restricted Share Unit plan, dated April 1, 2021, totaling 1,548,875 to certain eligible participants.
For further information, please contact:
Igal Sudman, Chairman, Chief Executive Officer and Corporate Secretary
Ayurcann Holdings Corp.
About Ayurcann Holdings Corp.:
Ayurcann is a leading post-harvest solution provider with a focus on providing and creating custom processes and pharma grade products for the adult use and medical cannabis industry in Canada. Ayurcann is focused on becoming the partner of choice for leading Canadian cannabis brands by providing best-in-class, proprietary services including ethanol extraction, formulation, product development and custom manufacturing.
Neither the Canadian Securities Exchange nor its Regulation Services Provider have reviewed or accept responsibility for the adequacy or accuracy of this release.
News Provided by GlobeNewswire via QuoteMedia
A planned business merger between two leading cannabis producers hit a small delay this week as a critical vote got moved.
Keep reading to find out more cannabis highlights from the past five days.
Tilray delays critical shareholder meeting
On Thursday (April 15), Tilray (NASDAQ:TLRY) announced it will be postponing its shareholder vote on the fate of its merger with Aphria (NASDAQ:APHA,TSX:APHA). It will take place on April 30 instead of April 16.
Neither cannabis company offered an explanation for the change. Tilray has asked shareholders to participate in this vote regardless of how many shares they may hold. “Tilray stockholders who have not already voted, or wish to change their vote, are strongly encouraged to do so,” the company said.
This news came days after Aphria shareholders overwhelmingly voted in favor of the business transaction, with a total of 99.38 percent of shareholders voting for the deal to continue. Confirmation from Aphria Chairman and CEO Irwin Simon indicated the partnership was en route to being complete.
This past week Aphria also released financial results for the third quarter of its 2021 fiscal year, in which the firm highlights the overall direction of the company with the Tilray deal.
“We expect to have a tremendous runway for long-term sustainable growth as we build upon our existing foundation in Canada and internationally by increasing the scale of our global operations,” Simon said in a statement.
Cannabis retailer celebrates digital trend
Bidding for the piece, named “Non-Fungible Toke“ started at a price of C$4.20. The retailer plans to donate the proceeds to two charities, Second Harvest and Less.
The latter is designed to counter the carbon footprint of blockchain technology, a common criticism drawn against the rise of NFTs and other novel technologies.
As of 11:00 a.m. EST on Friday (April 16), the NFT bid was up to C$169.11.
Cannabis company news
- The Valens Company (TSX:VLNS,OTCQX:VLNCF) issued its financial report for the first quarter of its 2021 fiscal year. In its results, the company highlights a net revenue uptick of 24.7 percent from the previous quarter, resulting in C$20 million for the period.
- Trulieve Cannabis (CSE:TRUL,OTCQX:TCNNF) closed a public offering of 5 million subordinate voting shares at a price of C$50 each for total gross proceeds of C$287.5 million. The company celebrated its financial position after an offering in January, which will lead to the pursuit of merger and acquisition targets.
- Australis Capital (CSE:AUSA,OTCQB:AUSAF) appointed Jason Dyck as its new chief science officer and chairman of the firm’s scientific advisory board. Dyck previously served as an executive at Aurora Cannabis (NASDAQ:ACB,TSX:ACB), leading the scientific efforts for the cannabis producer. “I look forward to providing AUSA with advice and direction in its scientific efforts towards bringing innovations to market with immediate and significant commercial appeal,” Dyck said.
- Truss Beverage, a cannabis drinks venture co-owned by Molson Coors Beverage Company (NYSE:TAP,TSX:TPX) and HEXO (NYSE:HEXO,TSX:HEXO), released the details of its new lineup of infused beverages. Six new drinks will become available around the summer and are intended to pair with the season.
Don’t forget to follow us @INN_Cannabis for real-time updates!
Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.
Partnerships with Minardi Law , Minorities for Medical Marijuana, CultivatED, and the Georgia Justice Project will include clinics and virtual events across Florida , Georgia , and Massachusetts
Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) (“Trulieve” or “the Company”), a leading and top-performing cannabis company based in the United States announced today a series of expungment clinics located throughout south and central Florida as well as virtual events in Georgia and Massachusetts . The clinics are part of the Company’s celebration of the 50 th anniversary of 420.
During the month of April, Minardi Law has hosted expungment clinics and will be hosting two more as follows:
- Releaf Patient Appreciation Day, April 17 th ( Valrico )
- First Annual 4/20 Event ( St. Petersburg Beach )
At these clinics, an attorney will be present to review records and see if someone is eligible for a sealing or expungment of their records. As part of the events, Trulieve will be helping cover the costs for finger prints, legal fees, and court costs.
Trulieve is working with Minorities for Medical Marijuana (“M4MM”) to host a 4/20 Expungement Clinic, part of M4MM’s Project Clean Slate. This event will take place on Saturday, April 24, 2021 , from 9:30am – 4:30pm at Riviera Beach City Hall. Anyone seeking to take place in this event is required to register in advance at http://trulieve.cc/expungementpreregistration .
In addition, Trulieve is sponsoring the First Friday Series , a weekly virtual event from the Georgia Justice Project to help Georgia citizens with record restrictions, and is also sponsoring the Fellowship Presentation and Expungement Clinic being offered through CultivateEd and GBLS on Friday, April 23 from 3:00pm – 4:00pm . You can register for the Massachusetts expungement clinic in advance here: HTTPS://BIT.LY/2Q655KK
“Our mission as a company has always been to improve people’s lives,” said Trulieve CEO Kim Rivers . “We’ve always been dedicated to improving the communities we call home. Partnering with Minardi Law , Minorities for Medical Marijuana, Georgia Justice Project and CultivatED on these clinics was a simple decision for us; we encourage anyone seeking help with the expungement process to attend one of these clinics in your own state to start the process.”
For more information about Trulieve and the April expungment clinics, please visit www.Trulieve.com .
Trulieve is primarily a vertically integrated “seed-to-sale” company in the U.S. and is the first and largest fully licensed medical cannabis company in the State of Florida . Trulieve cultivates and produces all of its products in-house and distributes those products to Trulieve-branded stores (dispensaries) throughout the State of Florida , as well as directly to patients via home delivery. Trulieve also has operations in California , Massachusetts , Connecticut and Pennsylvania. Trulieve is listed on the Canadian Securities Exchange under the symbol TRUL and trades on the OTCQX market under the symbol TCNNF.
To learn more about Trulieve, visit www.Trulieve.com .
SOURCE Trulieve Cannabis Corp.
News Provided by PR Newswire via QuoteMedia
Seth Rogen’s New Cannabis Brand are Now Available at Apothecarium Dispensaries in San Francisco , Berkeley and Capitola
The Apothecarium is offering cannabis from Houseplant, the cannabis lifestyle brand founded by Seth Rogen and Evan Goldberg at its five California dispensaries. The Apothecarium has three San Francisco locations (Castro, SOMA and Marina ) and one each in Berkeley and Capitola (outside of Santa Cruz ).
“With the vast number of dispensaries in California , we put a lot of effort into identifying the right ones that align with Houseplant’s values,” said Seth Rogen , Co-Founder of Houseplant. “The Apothecarium shares the same commitment to creating a strong consumer experience that we pride ourselves on and we are thrilled to bring our three initial strains to their stores in the Bay Area.”
Houseplant is launching with three flower strains, all of which will be available at The Apothecarium, including: Diablo Wind (sativa), Pancake Ice (sativa) and Pink Moon (indica). Like their founder’s groundbreaking film “Pineapple Express”, Houseplant strains are named after weather phenomena. Each strain will be sold in a custom tin.
“We are so proud to be one of the very first dispensaries in California to offer Houseplant to our customers,” said Ryan Hudson , CEO and co-founder of The Apothecarium. “Seth, Evan and everyone at Houseplant love and respect cannabis as much as we do. We simply cannot wait to share their beautiful and delicious flowers with our guests.”
“We’ve been working with the Houseplant team for more than a year and are grateful to have a partner that shares so many of our values, including an emphasis on cannabis education, quality, reform of cannabis laws and beautifully designed, recyclable packaging.”
“Seth has been hands-on during the process, spending time with our store managers to make sure they know the products and how much care has gone into vetting and selecting the best strains. We think our guests are going to love Houseplant.”
About The Apothecarium
The Apothecarium is recognized as one of the nation’s premier cannabis dispensaries, with an emphasis on education via in-depth one-on-one consultations from highly trained cannabis consultants. The company was founded by three first cousins and two family friends in 2011. Our dispensaries are known for providing educational events that are open to the public at no cost — and for welcoming seniors, first-time dispensary visitors, and people with serious medical conditions. The Apothecarium’s flagship San Francisco dispensary was named the best-designed dispensary in the country by Architectural Digest . Patients and customers may order at our dispensaries or online for pickup or delivery at apothecarium.com [apothecarium.com] .
The Apothecarium is committed to giving back to the communities we serve. We have donated more than $400,000 in cash to community groups and nonprofits — plus more than $300,000 worth of in-kind donations.
All Apothecarium dispensaries continue to implement safety measures to protect guests and team members. Protocols include strict social distancing inside and outside the dispensaries, a mask requirement for everyone inside the dispensaries, no contact check-in procedures and ongoing sanitizing throughout the day.
CA Licenses: C10-0000523-LIC; C10-0000522-LIC; C10-0000515-LIC, C10-0000738-LIC, C10-0000706-LIC
News Provided by Canada Newswire via QuoteMedia
MISSISSAUGA, Ontario TheNewswire – April 16, 2021 Sire Bioscience Inc. (CSE:SIRE) (OTC:BLLXF) (FSE:BR1B) (CNSX:SIRE.CN) (“SIRE” or the “Company”) announces that Brian Nugent has resigned as a member of the Company’s board of directors (the “ Board ”). It has been a pleasure and a blessing to have worked with Brian Nugent over the past few years, his business acumen and tremendous experience will certainly be missed, SIRE wishes him nothing but the best in all his future endeavors.
About Sire Bioscience
SIRE is headquartered in Mississauga, Ontario with its wholly owned subsidiary PLANTFUEL® based in Denver, Colorado. SIRE is managed by a group of successful entrepreneurs who have extensive experience in the areas of consumer-packaged goods, manufacturing, logistics, and distribution. SIRE is a CPG life science company focused on the plant-based foods and supplements industry.
For additional information contact:
Sire Bioscience Inc.
Copyright (c) 2021 TheNewswire – All rights reserved.
News Provided by TheNewsWire via QuoteMedia